EKO / TSX Venture Exchange
MONTREAL, June 30 /CNW Telbec/ - Noveko International Inc. (the
"Corporation") and the Sellers of all the share of Purer Life Technology Co.
Ltd. have agreed to postpone at the latest on July 31, 2008, the closing of
this acquisition. Since the last postponement of the closing date some of the
Corporation's requirements have been met. "But, we want to be sure to set up
all the required steps in order to achieve all the goals that the
Corporation's management wishes to reach with this acquisition. We strongly
believe that this acquisition will close at the latest on such date" said
Mr. André Leroux, Chairman of the Board and Chief Executive Officer.
Stepping down of Mr. Jacques Tessier as Senior Executive
The Corporation also announces that Mr. Jacques Tessier, Vice-President
and Chief Financial Officer of the Corporation, is stepping down by mutual
consent with the management from his duties in the Corporation; he will
remain, however, as a consultant for the Corporation, mainly in connection
with cash management and to insure a smooth transition with his successor. The
Corporation is confident that it will be able to announce shortly the name of
Noveko wishes to remind holders of its warrants issued on May 31, 2007
(the "Warrants") that the Warrants Exercise Period has been reduced from May
31, 2009 to June 30, 2008 in accordance with the terms and conditions of these
Warrants. If you wish to exercise the Warrants that you hold and which are
expiring today, you must contact without delay your stockbroker in order to do
so. We remind you that the exercise price of such Warrants is $3.35. As of
Friday, June 27, 2008, a total number of 3,112,500 Class A Shares have been
issued further to the exercise of such Warrants.
Noveko International Inc. is a public holding company. Currently, its
operating subsidiaries are S.A.S. ECM, Noveko Inc., Laboratoire SyMa Inc.,
Bolduc Leroux Inc. and Magnum Pharmaceutics Inc. ECM specializes in portable
real-time ultrasound scanners for veterinary and human medicine. Noveko Inc.
develops biomedical and environmental products derived from its patented
antimicrobial filtration technology (Noveko(TM) antimicrobial face masks and
air filters). SyMa specializes in sanitizers, sold under the Azuro(TM) brand.
Magnum acts as a manufacturer sales agent for the Noveko Group's biomedical
and environmental products and sanitizers and for other manufacturers. BLI is
involved in the custom processing and distribution of steel products based on
The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange has
not reviewed and does not accept responsibility for the adequacy or accuracy
of this release.
For further information:
For further information: André Leroux, Chairman of the Board and Chief
Executive Officer; Alain Bolduc, President and Chief Operating Officer, Noveko
International Inc., (514) 344-3030, http://www.noveko.com